Investment Summary |
|
|---|---|
| Date | 2022-04-20 |
| Target | Satellite Bio |
| Sector | Life Science |
| Investor(s) | Polaris Partners |
| Deal Type | Venture |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Polaris Partners is primarily a seed, first round, and early stage venture capital investor in information technology and life science businesses. However, Polaris also focuses on private equity investments in established companies. In this area, Polaris targets high growth middle market companies in industries including technology, healthcare, digital media, consumer products and services, and business services. The firm's investments include minority growth equity investments, recapitalizations with liquidity, and leveraged buyouts. Polaris Partners was formed in 1996 and has offices in Seattle, Washington and Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 84 of 87 |
| Sector: Life Science M&A | 37 of 39 |
| Type: Venture M&A Deals | 55 of 57 |
| State: Massachusetts M&A | 27 of 27 |
| Country: United States M&A | 76 of 78 |
| Year: 2022 M&A | 3 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-08 |
TRex Bio
San Francisco, California, United States TRex Bio is identifying and advancing a pipeline of medicines for debilitating inflammatory conditions by targeting the underlying dysregulation that drives disease. TRex Bio was founded in 2018 and is based in San Francisco, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-09 |
Tessa Therapeutics
Singapore, Singapore Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. Tessa Therapeutics is based in Singapore. |
Buy | - |
